Citation

Weller EB, Weller RA, Davis GP. Depress. Anxiety 2000; 12(Suppl 1): 85-89.

Affiliation

Department of Child and Adolescent Psychiatry, Children's Hospital of Philadelphia, Pennsylvania 19104, USA. weller@email.chop.edu

Copyright

(Copyright © 2000, John Wiley and Sons)

DOI

10.1002/1520-6394(2000)12:1+<85::AID-DA12>3.0.CO;2-0

PMID

11098420

Abstract

Pediatric psychopharmacology is hindered by the relative lack of controlled, empirical clinical trials [Shatzberg and Nemeroff, 1998: Washington, D.C.: The American Psychiatric Press, Inc. p 301-306]. Psychiatric disorders in children and adolescents carry considerable morbidity, impede development, and carry a significant mortality by suicide. Therefore, there is a need for studies of antidepressants and other psychotropics in children and adolescents. This article reviews the preliminary evidence that venlafaxine (Effexor), a novel antidepressant, may be useful in children and adolescents with a variety of psychiatric disorders.

Language: en